Abstract:Abstract Purpose: MET inhibitors are in clinical trials against several cancer types, but the mechanisms toward vulnerability remain elusive. Here we characterized the molecular basis of MET amplification (METamp) and HGF-autocrine driven tumors in response to MET tyrosine kinase inhibitors (TKI) and neutralizing antibodies. Experimental Design: METamp (MKN45 and MHCC97H) and HGF-autocrine activation (JHH5 and U87) cells were treated by the MET kinase inhibitor (INC280) and the anti-MET monoclonal antibody (MetMab) to determine the sensitivity and biological responses in vitro. Tumor inhibition was evaluated in vivo using SCID and SCIDhgf mouse models, respectively. HGF-mediated angiogenesis was measured by using the human endothelial cells (HUVEC) tube formation assay. Results: MKN45 and MHCC97H cells are more sensitive than JHH5 and U87 cells to INC280 treatment but are unresponsive to MetMab. In METamp cells, INC280 induced a DNA damage response with activation of repair through the p53BP1/ATM signaling pathway. Although INC280 and MetMab showed a moderate inhibitory effect on - JHH5 and U87 cells in vitro, both treatments potently suppressed tumor growth in mouse models. We found that HGF stimulation promotes human HUVEC cell tube formation via the Src pathway. INC280 or MetMab inhibited tube formation; thus in HGF-autocrine tumors, the endothelial cells are the secondary targets of tumor-derived HGF and MET inhibition. Conclusion: METamp and HGF-autocrine activation favor different molecular mechanisms, such as a DNA damage response or angiogenesis. Because individual types of MET oncogenic activation may respond to MET inhibitors differently, combination strategies should be developed based upon the molecular subtypes of the tumors. Citation Format: Jianqun Kou, Ben Staal, Phillip R. Musich, Liang Kang, Yuan Qin, Zhi Q. Yao, Boheng Zhang, Tam Angela, Alan Huang, Huaixiang Hao, George F. Vande Woude, Qian Xie. Differential therapeutic responses of MET oncogenic activations to Met kinase inhibitor and neutralizing antibody [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-015.

Supplemental Figure 4 Dose-dependent Inhibition from Acquired <i>met</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Supplemental Figure 3 Functional Validations of MET Y1248H and D1246N from Acquired <i>met</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Supplemental Figure 2 Clonal Progression of P02 and P04. from Acquired <i>met</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Figure S4 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Figure S3 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Supoemental Figure 1 Patiens Do Not Carry T790M Mutation Prior to MET-TKI Are More Likely to Have Longer PFS from Acquired <i>met</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Supplementary Figures 1-6 from Combined EGFR/MET or EGFR/HSP90 Inhibition is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Mutations in the MET Tyrosine Kinase Domain and Resistance to Tyrosine Kinase Inhibitors in Non-Small-cell Lung Cancer

Supplementary Figure 6 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure S1 from MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING

A Pooled Analysis of Clinical Outcome in Driver-Gene Negative Non-Small Cell Lung Cancer Patients with MET Overexpression Treated with Gumarontinib

Integrative Genomic Analysis of Drug Resistance in MET Exon 14 Skipping Lung Cancer Using Patient-Derived Xenograft Models

Supplementary Figure 1 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Supplementary Figure 9 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer

Supplementary Figure 7 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Abstract LB-015: Differential Therapeutic Responses of MET Oncogenic Activations to Met Kinase Inhibitor and Neutralizing Antibody

Supplementary Figure 11 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 5 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib Versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis

Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation

Supplemental Figure 4 Dose-dependent Inhibition from Acquired &lt;i&gt;met&lt;/i&gt; Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Supplemental Figure 3 Functional Validations of MET Y1248H and D1246N from Acquired &lt;i&gt;met&lt;/i&gt; Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Supplemental Figure 2 Clonal Progression of P02 and P04. from Acquired &lt;i&gt;met&lt;/i&gt; Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer